---
title: "Wegovy (semaglutide) in chronic weight management: Specific populations questions"
description: "Specific populations questions on Wegovy (semaglutide) in chronic weight management, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Adolescents. Questions: How much weight do teenagers lose on Wegovy (STEP TEENS)? How many teenagers on Wegovy reduce their BMI by at least 5%, 10%, or 15%? Can teenagers take Wegovy? What is the Wegovy maintenance dose for teenagers? 2 further questions follow. 6 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/specific-populations"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Wegovy (semaglutide) in chronic weight management: Specific populations questions

Manufacturer: Novo Nordisk Inc.  
Prescribing information: [Wegovy](https://www.novo-pi.com/wegovy.pdf)

Specific populations questions that apply to every indication of Wegovy are on [Wegovy (semaglutide), all indications: Specific populations](https://www.evicenter.com/medical-information/wegovy/specific-populations).

## Adolescents

<a id="wegovy-teens-step-teens"></a>

### How much weight do teenagers lose on Wegovy (STEP TEENS)?

Applies to: Chronic weight management in pediatric patients aged 12 years and older with obesity (Wegovy injection)

> “STEP TEENS<sup>3,4</sup>: A 68-week trial of 201 adolescent patients aged 12 to <18 years with a BMI in the 95<sup>th</sup> percentile or higher (according to sex- and age-specific growth charts). Patients were required to have at least one unsuccessful dietary weight-loss attempt and also completed a 12-week lifestyle intervention run-in phase. Patients were randomized in a 2:1 ratio to once-weekly Wegovy<sup>®</sup> 2.4 mg injection or placebo for 68 weeks (including a 16-week dose escalation). Patients in both arms also received behavioral lifestyle therapy, consisting of counseling on healthy nutrition and physical activity for weight loss (a goal of 60 minutes/day of physical activity). The 68-week treatment period was followed by a 7-week follow-up period during which patients did not receive Wegovy<sup>®</sup> or placebo. During the trial, 10% of patients in each of the Wegovy<sup>®</sup> and placebo arms discontinued treatment.”

Source: [WEGOVY: Wegovy® For Adolescent, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/adolescent-indication.html#:~:text=STEP,and%20placebo%20arms%20discontinued%20treatment.)

> “16.1% mean reduction in BMI with Wegovy<sup>®</sup>
>
>  vs 0.6% (0.2 kg/m<sup>2</sup>) mean increase in BMI with placebo at 68 weeks”

Source: [WEGOVY: Wegovy® For Adolescent, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/adolescent-indication.html#:~:text=16.1%25%20mean%20reduction%20in%20BMI,with%20placebo%20at%2068%20weeks)

> “16.7% estimated difference between Wegovy<sup>®</sup> (-16.1%) and placebo (+0.6%) at 68 weeks<sup>3</sup>”

Source: [WEGOVY: Wegovy® For Adolescent, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/adolescent-indication.html#:~:text=16.7%25%20estimated%20difference%20between,and%20placebo%20%28%2B0.6%25%29%20at%2068)

> “<sup>‡</sup>Missing data were imputed from retrieved subjects of the same randomized treatment arm.<sup>3</sup>”

Source: [WEGOVY: Wegovy® For Adolescent, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/adolescent-indication.html#:~:text=data%20were%20imputed%20from%20retrieved%20subjects%20of%20the%20same%20randomized%20treatment)

> “<sup>§</sup>p<0.0001 (unadjusted 2-sided) for superiority.<sup>3</sup>”

Source: [WEGOVY: Wegovy® For Adolescent, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/adolescent-indication.html#:~:text=%28unadjusted%202%2Dsided%29%20for)

> “14.7% (~36 lb) mean weight
> reduction with Wegovy<sup>®</sup> 
>
> vs 2.7% (~6 lb) mean weight increase
> with placebo at 68 weeks<sup>†</sup>”

Source: [WEGOVY: Wegovy® For Adolescent, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/adolescent-indication.html#:~:text=14.7%25%20%28~36%20lb%29%20mean%20weight,with%20placebo%20at%2068)

> “<sup>†</sup>Supportive secondary end points were not included in the statistical testing hierarchy and, as such, not controlled for multiplicity.<sup>4</sup>”

Source: [WEGOVY: Wegovy® For Adolescent, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/adolescent-indication.html#:~:text=secondary%20end%20points%20were%20not,as%20such%2C%20not%20controlled%20for)

<a id="wegovy-teens-bmi-thresholds"></a>

### How many teenagers on Wegovy reduce their BMI by at least 5%, 10%, or 15%?

Applies to: Chronic weight management in pediatric patients aged 12 years and older with obesity (Wegovy injection)

> “Table 18. Changes in Weight and BMI at Week 68 in Pediatric Patients with Obesity 
> Aged 12 Years and Older in Study 10 with WEGOVY<sup>®</sup> 2.4 mg Injection in 
> Study 10
> Intention-to-Treat<sup>a</sup>
> PLACEBO
> N=67
> WEGOVY<sup>®</sup> 2.4 mg Injection
> N=134
> BMI
> Baseline mean (kg/m<sup>2</sup>)
> 35.7
> 37.7
> % change from baseline in BMI (LSMean)
> 0.6
> -16.1
> % difference from placebo (LSMean) (95% CI)
> -16.7 (-20.3; -13.2)*
> % of Patients with greater than or equal to 5% 
> reduction in baseline BMI<sup>b</sup>
> 19.7
> 77.1
> % difference from placebo (LSMean)
> 57.4
> % of Patients with greater than or equal to 10% 
> reduction in baseline BMI<sup>b</sup>
> 7.7
> 65.1
> % difference from placebo (LSMean) 
> 57.5
> % of Patients with greater than or equal to 15% 
> reduction in baseline BMI<sup>b</sup>
> 4
> 57.8
> % difference from placebo (LSMean)
> 53.9”

Source: [WEGOVY: Prescribing information, page 16, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=16)

> “<sup>a</sup> The intention-to-treat population includes all randomized patients. Missing data were imputed using available data 
> according to value and timing of last available observation on treatment and endpoint’s baseline value from retrieved 
> subjects (RD-MI). At Week 68, the BMI was missing for 2.2% and 7.5% of patients randomized to WEGOVY<sup>®</sup> injection 
> and placebo, respectively.”

Source: [WEGOVY: Prescribing information, page 16, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=16)

> “<sup>b</sup> Parameters not included in the pre-specified hierarchical testing.”

Source: [WEGOVY: Prescribing information, page 16, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=16)

> “* p<0.0001 (unadjusted 2-sided) for superiority.”

Source: [WEGOVY: Prescribing information, page 16, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=16)

Note: In the Table 18 rows, the first value is placebo and the second is WEGOVY 2.4 mg injection. Study 10 of the Prescribing Information has the same design and enrollment (68 weeks, 201 patients aged 12 years and older) as STEP TEENS on the Wegovy HCP site.

<a id="wegovy-teens-who-can-use"></a>

### Can teenagers take Wegovy?

Applies to: Chronic weight management in pediatric patients aged 12 years and older with obesity (Wegovy injection)

> “The safety and effectiveness of WEGOVY<sup>®</sup> injection in combination with a reduced-calorie diet and 
> increased physical activity to reduce excess body weight and maintain weight reduction long term 
> in pediatric patients aged 12 years and older with obesity have been established. Use of WEGOVY<sup>®</sup> 
> injection for this indication is supported by a 68-week, double-blind, placebo-controlled clinical trial 
> in 201 pediatric patients aged 12 years and older with a BMI corresponding to ≥95th percentile for 
> age and sex [see Clinical Studies (14.3)] and from trials in adult patients with obesity [see Clinical 
> Studies (14.2)]. Use of the 1.7 mg once weekly maintenance dosage of WEGOVY<sup>®</sup> injection in pediatric 
> patients is also supported by additional exposure-efficacy and safety analyses in pooled adult and 
> pediatric patients.”

Source: [WEGOVY: Prescribing information, page 7, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=7)

> “The safety and effectiveness of WEGOVY<sup>®</sup> injection have not been established in pediatric patients:
> •	to reduce the risk of major adverse CV events. Clinical trials for this indication are highly 
> impracticable because of the low prevalence of the condition in pediatric patients.
> •	to reduce excess body weight and maintain weight reduction long term with the 7.2 mg once 
> weekly dosage.
> •	to reduce excess body weight and maintain weight reduction long term in those less than 12 
> years of age.
> •	for the treatment of noncirrhotic MASH.
> The safety and effectiveness of WEGOVY<sup>®</sup> tablets have not been established in pediatric patients.”

Source: [WEGOVY: Prescribing information, page 7, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=7)

<a id="wegovy-teens-dose"></a>

### What is the Wegovy maintenance dose for teenagers?

Applies to: Chronic weight management in pediatric patients aged 12 years and older with obesity (Wegovy injection)

> “Weight Reduction in Pediatric Patients Aged 12 Years and Older
> •	The maintenance dosage of WEGOVY<sup>®</sup> injection for weight 
> reduction in pediatric patients aged 12 years and older is 
> either 2.4 mg (recommended), or 1.7 mg once weekly.
> •	Consider treatment response and tolerability when selecting 
> the maintenance dosage [see Adverse Reactions (6.1), 
> Clinical Studies (14.3)].”

Source: [WEGOVY: Prescribing information, page 3, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=3)

<a id="wegovy-teens-side-effects"></a>

### What side effects do teenagers have on Wegovy?

Applies to: Chronic weight management in pediatric patients aged 12 years and older with obesity (Wegovy injection)

> “Table 5 shows adverse reactions reported in greater than or equal 
> to 3% of WEGOVY<sup>®</sup> injection-treated pediatric patients and more 
> frequently than in the placebo group from a trial in pediatric patients 
> aged 12 years and older. 
> Table 5. Adverse Reactions (≥3% and Greater than 
> Placebo) in WEGOVY<sup>®</sup> 2.4 mg Injection-
> treated Pediatric Patients Aged 12 Years and 
> Older with Obesity for Weight Reduction
> Placebo
> N=67
> %
> WEGOVY<sup>®</sup> 
> Injection (2.4 mg 
> Once Weekly)
> N=133
> %
> Nausea
> 18
> 42
> Vomiting
> 10
> 36
> Diarrhea
> 19
> 22
> Headache
> 16
> 17
> Abdominal Pain
> 6
> 15
> Nasopharyngitis
> 10
> 12
> Dizziness
> 3
> 8
> Gastroenteritis
> 3
> 7
> Constipation
> 2
> 6
> Gastroesophageal Reflux 
> Disease
> 2
> 4
> Sinusitis
> 2
> 4
> Urinary tract infection
> 2
> 4
> Ligament sprain
> 2
> 4
> Anxiety
> 2
> 4
> Hair Loss
> 0
> 4
> Cholelithiasis
> 0
> 4
> Eructation
> 0
> 4
> Influenza
> 0
> 3
> Rash
> 0
> 3
> Urticaria
> 0
> 3”

Source: [WEGOVY: Prescribing information, page 5, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=5)

> “In the pediatric clinical trial for weight reduction, 62% of WEGOVY<sup>®</sup> 
> injection-treated patients and 42% of placebo-treated patients 
> reported gastrointestinal adverse reactions. The most frequently 
> reported reactions were nausea (42% vs. 18%), vomiting (36% vs. 
> 10%), and diarrhea (22% vs. 19%). Other gastrointestinal-related 
> reactions that occurred at a higher incidence than placebo among 
> WEGOVY<sup>®</sup> injection-treated pediatric patients included abdominal 
> pain, constipation, eructation, gastroesophageal reflux disease, 
> dyspepsia, and flatulence.”

Source: [WEGOVY: Prescribing information, page 6, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=6)

> “Adverse reactions with WEGOVY<sup>®</sup> injection treatment in pediatric patients aged 12 years and older 
> were generally similar to those reported in adults. Pediatric patients aged 12 years and older treated 
> with WEGOVY<sup>®</sup> injection had greater incidences of cholelithiasis, cholecystitis, hypotension, rash, 
> and urticaria compared to adults treated with WEGOVY<sup>®</sup> [see Adverse Reactions (6.1)].”

Source: [WEGOVY: Prescribing information, page 7, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=7)

Note: Table 5 columns are placebo (N=67) then WEGOVY 2.4 mg injection (N=133), in % of patients.

## Specific populations

<a id="wegovy-older-adults"></a>

### Can adults 65 and older take Wegovy?

Applies to: Adults aged 65 and older receiving Wegovy for weight reduction

> “A reduction in body weight was observed with WEGOVY<sup>®</sup> irrespective of age, sex, race, ethnicity, BMI at baseline, body weight (kg) 
> at baseline, and level of renal function impairment.”

Source: [WEGOVY: Prescribing information, page 11, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=11)

> “In the WEGOVY<sup>®</sup> injection clinical trials for weight reduction and long-term maintenance, 233 (9%) 
> WEGOVY<sup>®</sup> injection-treated patients were aged 65 to less than 75 years and 23 (1%) WEGOVY<sup>®</sup> 
> injection-treated patients were aged 75 years and older [see Clinical Studies (14.2)]. In a WEGOVY<sup>®</sup> 
> 25 mg tablets clinical trial for weight reduction and long-term maintenance, 16 (8%) WEGOVY<sup>®</sup> 
> tablets-treated patients were aged 65 to less than 75 years and 5 (2%) WEGOVY<sup>®</sup> tablet-treated 
> patients were aged 75 years and older [see Clinical Studies (14.2)].”

Source: [WEGOVY: Prescribing information, page 7, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=7)

> “In a CV outcomes trial, 2,656 (30%) WEGOVY<sup>®</sup> injection-treated patients were aged 65 to 75 years 
> and 703 (8%) WEGOVY<sup>®</sup> injection -treated patients were aged 75 years and older [see Clinical Studies 
> (14.1)]. No overall difference in the effectiveness was observed between patients aged 65 years and 
> older and younger adult patients.”

Source: [WEGOVY: Prescribing information, page 7, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=7)

> “In the CV outcomes trial, patients aged 75 years and older reported 
> more hip and pelvis fractures in the WEGOVY<sup>®</sup> injection-treated patients than placebo-treated patients. 
> Patients aged 75 years and older (WEGOVY<sup>®</sup> injection-treated and placebo-treated) reported more 
> serious adverse reactions overall compared to younger adult patients [see Adverse Reactions (6.1)].”

Source: [WEGOVY: Prescribing information, page 7, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=7)

Note: The effectiveness statement and the fracture finding are from the CV outcomes trial in adults with established cardiovascular disease and either obesity or overweight.

## Related pages
- [Medical information: Wegovy (semaglutide): Chronic weight management](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management)
- [Indication](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/access-and-coverage)
